OpGen Inc. said it regained compliance with Nasdaq's minimum bid price requirement and will continue to trade on the stock exchange.
The developer of laboratory tests added that it was in compliance with all of Nasdaq's applicable listing standards and so its hearing before the Nasdaq hearings panel has been canceled.
OpGen recently implemented a 1-for-25 reverse stock split to increase the per-share market price of its common stock in connection with Nasdaq regulations.
